Tesamorelin

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog developed by Theratechnologies. It consists of the 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus, which enhances its stability and bioavailability. It is FDA-approved under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

The peptide functions by stimulating GHRH receptors in the anterior pituitary, promoting the natural synthesis and secretion of growth hormone. The resulting GH elevation leads to increased lipolysis, particularly in visceral adipose tissue. Tesamorelin's mechanism preserves the physiological pulsatile pattern of GH release and the natural feedback regulation of the GH axis.

Clinical trials have demonstrated that Tesamorelin significantly reduces trunk fat, visceral adipose tissue, and triglyceride levels while improving body image perception. Studies showed an average 15% reduction in visceral fat after 26 weeks of treatment. Its FDA-approved status provides a robust evidence base from multiple Phase III clinical trials, making it one of the best-validated peptides for fat reduction.